Navigation Links
Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
Date:5/9/2011

of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to agree with the FDA on the design and feasibility of a cardiovascular outcomes trial, Orexigen's ability to conduct such a cardiovascular outcomes trial, Orexigen's ability to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to attract and retain key personnel; Orexigen's ability to maintain sufficient capital; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Quarterly Report on Form 10-Q, which we intend to file with the Securities Exchange Commission this week and will be available from the SEC's website (www.sec.gov) and on our website (www.orexigen.com) under the heading "Investor Relations." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Orexigen Therapeutics, Inc.Balan
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
2. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
3. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
6. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
7. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
10. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
11. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... S.C. , April 23, 2015 Once ... and strengthening our commitment to patient safety. ... the fight against infectious disease. The next ... Medical gas sensors are now mounted in the ... the need to open ceiling tiles potentially releasing dust ...
(Date:4/23/2015)... -- Research Solutions, Inc. (OTCQB: RSSS), a pioneer in providing on-demand ... life science companies, academic institutions, and other research intensive ... th Annual B. Riley & Co. Investor Conference ... Loews Hollywood Hotel in Los Angeles ... scheduled to present on Tuesday, May 12 th ...
(Date:4/23/2015)... AUGUSTA, Ga. , April 23, 2015 /PRNewswire/ ... of medical holography, has made its Voxgram hologram ... just-launched Kickstarter campaign: https://www.kickstarter.com/projects/629071847/holographic-optical-technologies?ref=nav_search ... first consumer product through the campaign, the eight-inch ... a reward, along with its more established, medical-grade ...
Breaking Medicine Technology:BeaconMedaes launches new Zone Valve Box Assembly 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 2Research Solutions to Present at the 16th Annual B. Riley & Co. Investor Conference on May 12, 2015 3Holographic Optical Technologies Launches Kickstarter, Offering True 3D Holograms 2
... Nov. 12 Zimmer Holdings, Inc. (NYSE: ZMH ; ... $1.0 billion of its senior unsecured notes in an underwritten ... 2019 and $500.0 million of 5.75% notes due 2039. The ... their Treasury benchmark, and the 30-year notes were priced at ...
... new treatment for autism appears to normalize brain function, ... BCIA-EEG. , In addition to high serotonin ... pattern reflecting impaired brain function, particularly in areas of ... bonding. , However, Quantitative EEG,s conducted ...
Cached Medicine Technology:Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2New Treatment for Autism 'Holds Promise' 2New Treatment for Autism 'Holds Promise' 3
(Date:4/24/2015)... Eastern Star Masonic Home is hosting an Open House to ... from 1:30-3:00 pm. , Residents from Boone and the surrounding ... opening of the new community room. Light refreshments will be ... to anyone who wishes to visit the rest of the ... be available for use by residents of the facility as ...
(Date:4/24/2015)... Buffalo, New York (PRWEB) April 24, 2015 ... has partnered with Allergy and Asthma Network (The Network), ... PURE Solutions will provide news, tips and information ... on The Network’s newly redesigned website. , The goal ... raising awareness about the travel needs of people with ...
(Date:4/24/2015)... 2015 E-Factor Diet claims to be a ... stress and allows people to enjoy food as rapid weight ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... blueprint that Jared used to lose weight, and all the ... included inside. This is a diet for people who are ...
(Date:4/24/2015)... Del Mar, CA (PRWEB) April 24, 2015 ... newest addition to the staff, Jamie Johansen. She will ... practice, including human resources, patient relations, and reporting. Jamie ... spa and cosmetic surgery sector as the new Practice ... Operations at LaserAway and Practice Manager at American Laser ...
(Date:4/23/2015)... 23, 2015 Fitnet , the only ... now, an accurate calorie counter during video exercise, is featured ... Health and Fitness categories in the Apple Watch App Store ... of the Digital age," now allows clients to use it ... only third party app providing accurate calorie burn counter, cardio ...
Breaking Medicine News(10 mins):Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2Health News:E-Factor Diet: Review Examining John Rowley’s Brand New Weight Loss Program Released 2Health News:Fitnet Handpicked as Top Healthy Living App in Apple Watch Store 2Health News:Fitnet Handpicked as Top Healthy Living App in Apple Watch Store 3
... discovered a protein signaling pathway that becomes hyperactivated in human ... be effective in the treatment of human sarcomas. The ... Cancer Cell . A team of researchers led ... and Chairman of the Department of Oncological Sciences at Mount ...
... St. Louis, MO 23 May, 2011 ... and medical information products and services, announced today ... (METI), a leading manufacturer of medical simulation and ... to release a turn-key health care education product ...
... researchers, including a number from the University of North Carolina ... the genome that contribute to the debilitating lung disease that ... provide insight into the causes of the wide variation in ... the way to new diagnostic markers and therapeutic approaches for ...
... the name of an infection that causes a series of reactions ... The problem for both patients and doctors is that the early ... a severe flu or winter vomiting disease. A researcher at Lund ... which shows both whether a patient has sepsis and how serious ...
... SUNDAY, May 22 (HealthDay News) -- New Swedish research ... major cardiovascular complications among patients who have a ... builds on earlier work that was published by the ... That study suggested that Inspra (eplerenone), an aldosterone antagonist, ...
... the Florida campus of The Scripps Research Institute have for ... natural product isolated from the bark of a plant widely ... foundation to develop an effective alternative to commonly prescribed narcotic ... in an advanced online edition of the journal Nature ...
Cached Medicine News:Health News:Mount Sinai researchers discover possible new target for sarcoma treatment and prevention 2Health News:Elsevier and METI collaborate to offer simulation technology for health science curriculums 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Quicker detection and treatment of severe sepsis 2Health News:Blood Pressure Drug Helps Those With Mild Heart Failure 2Health News:Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties 2Health News:Led by advances in chemical synthesis, scientists find natural product shows pain-killing properties 3
... a foldable silicone IOL. It features a ... designed to be inserted with The UNFOLDER® ... is the first and only FDA-approved multifocal ... a full range of functional visionnear, intermediate, ...
... with optimum molecular weight and viscosity, so ... coats and protects the delicate structures of ... balance of cohesion, adhesion, and pseudoplasticity to ... phaco surgeon expects from an ophthalmic viscoelastic ...
... Healon GV is a sterile, non-pyrogenic, ... purified, noninflammatory, high molecular weight (average ... sodium hyaluronate. Healon GV contains 14 ... in a physiological sodium chloride-phosphate buffer ...
... PROVISC ophthalmic viscosurgical device is ... characterized by high molecular weight, ... tension. It provides excellent space ... is easily removed. It is ...
Medicine Products: